Top

Journal of Radiation Oncology

Published in:

01-12-2019 | Digital Volume Tomography | Original Research

Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization

Authors: Alexander D. Sherry, Adam Stewart, Guozhen Luo, Austin N. Kirschner

Published in: Journal of Radiation Oncology | Issue 4/2019

Abstract

Objective

Intensity-modulated radiation therapy (IMRT) using a volumetric-modulated arc therapy technique may offer dosimetric and clinical benefits compared to the historical standard of care 3D conformal radiotherapy (3D-CRT) in definitive treatment of bladder cancer. We hypothesized that IMRT with CBCT would reduce dose to the rectum, bowel, and bladder compared to 3D-CRT.

Methods

We reviewed nineteen patients treated with maximal transurethral resection of bladder tumor followed by concurrent chemotherapy with IMRT. All patients received 45 Gy to the entire empty bladder followed by 19.8 Gy tumor boost treated with full bladder. 3D-CRT treatment plans were created for the same prescription. Paired t test or Wilcoxon matched-pairs signed rank test analyzed dosimetry and bladder volumes.

Results

The rectum and bowel V40, V45, V50, V55, and V60 were reduced by over 50% in the IMRT plans compared to 3D-CRT (p < 0.0001). IMRT also reduced volume of bladder irradiated compared to 3D-CRT (p < 0.01). After CBCT, patients were likely to undergo clinically significant shifts > 0.5 cm before boost delivery (p = 0.001). Bladder volumes were significantly lower during boost treatments compared to pre-treatment simulation (p = 0.002). There were 4 (21%) grade 3 genitourinary toxicities and 1 (5%) grade 3 gastrointestinal toxicity.

Conclusion

IMRT is superior to 3D-CRT for bladder cancer and spares dose to bowel, rectum, and bladder with improved acute toxicity compared to published clinical literature. For boost treatment, daily full bladder volume and positioning are not always reproducible, supporting the need for CBCT for optimal localization of the primary bladder tumor.

Available only for authorised users

Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576–3583. https://doi.org/10.1200/JCO.1998.16.11.3576 CrossRefPubMed

Sondergaard J, Holmberg M, Jakobsen AR et al (2014) A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer. Acta Oncol (Madr) 53:1321–1328. https://doi.org/10.3109/0284186X.2014.928418 CrossRef

Vestergaard A, Søndergaard J, Petersen JB et al (2010) A comparison of three different adaptive strategies in image-guided radiotherapy of bladder cancer. Acta Oncol (Madr) 49:1069–1076. https://doi.org/10.3109/0284186X.2010.501813 CrossRef

Baumann BC, Noa K, Wileyto EP, Bekelman JE, Deville C, Vapiwala N, Kirk M, Both S, Dolney D, Kassaee A, Christodouleas JP (2015) Adjuvant radiation therapy for bladder cancer: a dosimetric comparison of techniques. Med Dosim 40:372–377. https://doi.org/10.1016/j.meddos.2015.06.001 CrossRefPubMed

Lutkenhaus LJ, van Os RM, Bel A, Hulshof MCCM (2016) Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiat Oncol 11:45. https://doi.org/10.1186/s13014-016-0618-6 CrossRefPubMedPubMedCentral

Søndergaard J, Høyer M, Petersen JB et al (2009) The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol (Madr) 48:238–244. https://doi.org/10.1080/02841860802251575 CrossRef

Lee CY, Yang KL, Ko HL, Huang RY, Tsai PP, Chen MT, Lin YC, Hwang TI, Juang GD, Chi KH (2014) Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. Radiat Oncol 9:213. https://doi.org/10.1186/1748-717X-9-213 CrossRefPubMedPubMedCentral

Mizowaki T (2015) Intensity-modulated radiation therapy for locally advanced prostate cancer. In: Nishimura Y, Komaki R (eds) Intensity-modulated radiation therapy: clinical evidence and techniques. Springer, pp 379–402

Bauman G, Rumble RB, Chen J et al (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 24:461–473. https://doi.org/10.1016/j.clon.2012.05.002 CrossRef

10.

Xu D, Li G, Li H, Jia F (2017) Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: a systematic review and meta-analysis. Med 96:e7685. https://doi.org/10.1097/MD.0000000000007685 CrossRef

11.

Lemanski C, Thariat J, Ampil FL, Bose S, Vock J, Davis R, Chi A, Dutta S, Woods W, Desai A, Godinez J, Karlsson U, Mills M, Nguyen NP, Vinh-Hung V, International Geriatric Radiotherapy Group (2014) Image-guided radiotherapy for cardiac sparing in patients with left-sided breast cancer. Front Oncol 4:257. https://doi.org/10.3389/fonc.2014.00257 CrossRefPubMedPubMedCentral

12.

Block AM, Korpics M, Martin B, Solanki AA (2017) Intensity modulated radiation therapy in muscle-invasive bladder cancer: predictors of utilization and survival outcomes. Int J Radiat Oncol 99:E215–E216. https://doi.org/10.1016/j.ijrobp.2017.06.1119 CrossRef

13.

Solanki AA, Martin B, Korpics M et al (2017) Bladder-preserving therapy patterns of care: a survey of US radiation oncologists. Int J Radiat Oncol Biol Phys 99:383–387. https://doi.org/10.1016/j.ijrobp.2017.04.009 CrossRefPubMed

14.

Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU (2019) Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712—a randomized phase II trial. J Clin Oncol 37:44–51. https://doi.org/10.1200/JCO.18.00537 CrossRefPubMed

15.

Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU (2010) Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 76:S116–S122. https://doi.org/10.1016/j.ijrobp.2009.02.090 CrossRefPubMedPubMedCentral

16.

Meijer GJ, Van Der Toorn PP, Bal M et al (2012) High precision bladder cancer irradiation by integrating a library planning procedure of 6 prospectively generated SIB IMRT plans with image guidance using lipiodol markers. Radiother Oncol 105:174–179. https://doi.org/10.1016/j.radonc.2012.08.011 CrossRefPubMed

17.

Murthy V, Master Z, Adurkar P, Mallick I, Mahantshetty U, Bakshi G, Tongaonkar H, Shrivastava S (2011) “Plan of the day” adaptive radiotherapy for bladder cancer using helical tomotherapy. Radiother Oncol 99:55–60. https://doi.org/10.1016/j.radonc.2011.01.027 CrossRefPubMed

18.

Whalley D, Caine H, McCloud P, Guo L, Kneebone A, Eade T (2015) Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer. Radiat Oncol 10:205. https://doi.org/10.1186/s13014-015-0499-0 CrossRefPubMedPubMedCentral

19.

Van Rooijen DC, Van de Kamer JB, Pool R et al (2009) The effect of on-line position correction on the dose distribution in focal radiotherapy for bladder cancer. Radiat Oncol 4:38. https://doi.org/10.1186/1748-717X-4-38 CrossRefPubMedPubMedCentral

20.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8 CrossRef

21.

Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, el-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP (2016) Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy. Int J Radiat Oncol Biol Phys 96:78–86. https://doi.org/10.1016/j.ijrobp.2016.04.032 CrossRefPubMedPubMedCentral

22.

Lawton CAF, Michalski J, El-Naqa I et al (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74:383–387. https://doi.org/10.1016/j.ijrobp.2008.08.002 CrossRef

23.

Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071. https://doi.org/10.1200/JCO.2002.11.027 CrossRefPubMed

24.

Kavanagh BD, Pan CC, Dawson LA et al (2010) Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 76:S101–S107. https://doi.org/10.1016/j.ijrobp.2009.05.071 CrossRefPubMed

25.

McDonald F, Waters R, Gulliford S et al (2015) Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin Oncol 27:22–29. https://doi.org/10.1016/j.clon.2014.09.016 CrossRef

26.

James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, BC2001 Investigators (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477–1488. https://doi.org/10.1056/NEJMoa1106106 CrossRef

27.

Gulliford SL, Foo K, Morgan RC et al (2010) Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 76:747–754. https://doi.org/10.1016/j.ijrobp.2009.02.025 CrossRefPubMed

28.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27:4055–4061. https://doi.org/10.1200/JCO.2008.19.5776 CrossRefPubMedPubMedCentral

29.

Adams B, Diaz D, Pollack A, Abramowitz M (2014) Bladder carcinoma. In: Lee N, Riaz N, Lu J (eds) Target volume delineation for conformal and intensity-modulated radiation therapy. Springer International Publishing, Cham, pp 377–386CrossRef

30.

Della BC, Yorke E, Kollmeier MA (2014) Image guided radiation therapy for bladder cancer: assessment of bladder motion using implanted fiducial markers. Pract Radiat Oncol 4:108–115. https://doi.org/10.1016/j.prro.2013.07.008 CrossRef

31.

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White R, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148 CrossRefPubMed

32.

Huddart RA, Birtle A, Maynard L, Beresford M, Blazeby J, Donovan J, Kelly JD, Kirkbank T, McLaren D, Mead G, Moynihan C, Persad R, Scrase C, Lewis R, Hall E (2017) Clinical and patient-reported outcomes of SPARE—a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 120:639–650. https://doi.org/10.1111/bju.13900 CrossRefPubMedPubMedCentral

Title: Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization
Authors: Alexander D. Sherry
Adam Stewart
Guozhen Luo
Austin N. Kirschner
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Digital Volume Tomography
Radiotherapy
Digital Volume Tomography
Published in: Journal of Radiation Oncology / Issue 4/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-019-00411-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Temporalis muscle width as a measure of sarcopenia correlates with overall survival in patients with newly diagnosed glioblastoma

The utilization patterns and comparative effectiveness of systemic therapy with high-dose thoracic radiotherapy or low-dose thoracic radiotherapy versus systemic therapy alone in newly diagnosed metastatic non-small cell lung cancer patients

The value of prostate-specific antigen monitoring during salvage radiotherapy: a retrospective study and systematic review with meta-analysis

Complications and toxicity of re-irradiation following total laryngectomy for laryngeal cancer

Clinical outcomes and toxicity of proton radiotherapy for vestibular schwannomas: a systematic review

Outcome of surgery and radiotherapy for dermatofibrosarcoma protuberans: 5-year experience from two tertiary centers of eastern India

Keynote webinar | Spotlight on antibody–drug conjugates in cancer